Waters Corporation

Waters Corporation

WAT
Waters CorporationUS flagNew York Stock Exchange
411.52
USD
-1.99
- -
30.78BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
22.29
23.58
24.8
26.83
28.94
31.43
35.59
38.09
45.24
49.54
50.04
49.86
53.19
40.07
Basic EPS, GAAP
5.27
5.12
5.7
6.46
0.25
7.71
8.76
8.4
11.25
11.8
10.87
10.75
10.8
4.04
Free Cash Flow per Basic Share
4.29
4.81
5.71
6.78
7.61
6.6
7.09
9.95
9.4
7.14
7.48
10.44
9.07
3.28
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
20.79
22.79
25.34
28.77
28.16
21.44
-3.46
3.73
6.05
8.54
19.44
30.79
43.01
- -
Tangible Book Value per Share
13.84
15.76
18.26
21.78
20.74
13.19
-12.98
-7.56
-5.15
-2.59
-13.25
-0.59
11.13
- -
Basic Weighted Avg Shares
85
84
82
81
80
77
68
62
62
60
59
59
60
75
Sales/Revenue/Turnover
1,904
1,989
2,042
2,167
2,309
2,420
2,407
2,365
2,786
2,972
2,956
2,958
3,165
2,999
Operating Margin (%)
27.17
26.81
28.17
29
29.38
30.55
29.44
27.63
29.68
29.72
27.66
28.32
25.36
13.86
Depreciation Expense
80
94
90
96
106
108
105
125
132
130
166
192
206
312
Net Income, GAAP
450
432
469
522
20
594
592
522
693
708
642
638
643
302
Effective Tax Rate (%)
8.18
12.05
13.45
13.1
96.83
12.95
12.69
14.62
14.06
15.53
12.77
15.5
14.87
12.75
Profit Margin (%)
23.63
21.7
22.97
24.06
0.88
24.54
24.61
22.05
24.87
23.81
21.72
21.56
20.3
10.07
Working Capital
2,069
2,237
2,649
3,115
3,664
2,214
721
596
948
978
963
879
908
- -
LT Debt
- -
1,237
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1,763
1,895
2,059
2,302
2,234
1,567
-216
232
368
504
1,150
1,829
2,561
- -
Return on Invested Capital (%)
26.62
17.74
17.71
23.29
0.89
32.31
28.53
259.76
155.16
130.58
70.33
42.55
26.93
19.51
Return on Capital (%)
27.32
17.58
17.9
24.05
0.93
32.61
85.85
350.94
181.65
153.42
80.53
46.3
28.61
20.54
Return on Common Equity (%)
27.86
23.6
23.73
23.92
0.9
31.24
9.41
7.61
231.06
162.32
77.62
42.82
29.28
27.98

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
491
413
- -
LT Borrowings
947
4,855
- -
LT Finance Leases
53
302
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
98
98
Market Capitalization
22,618
29,234
36,816

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,148
4,064
- -
Cash, Cash Equivalents & STI
588
462
- -
Accounts Receivable, Net
829
1,753
- -
Inventories
572
1,496
- -
Total Current Liabilities
1,239
2,273
- -
Payables & Accruals
152
671
- -
ST Debt
491
413
- -
Deferred Revenue
267
520
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.95%
64.53%
40.07%
Free Cash Flow
3.25%
-0.37%
-12.88%
Net Income, GAAP
275.22%
5.16%
0.75%
Sales/Revenue/Turnover
4.62%
6.2%
6.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
637
709
740
873
2,958
2025
662
771
800
932
3,165
2026
1,267
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.73
2.41
2.72
3.9
10.75
2025
2.04
2.47
2.5
3.78
10.8
2026
-0.88
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Udit Batra
Full Time Employees
7,900
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
34 Maple Street Milford MA United States of America 01757
IPO Date
Nov 17, 1995
Website
waters.com
Business
Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.

Company News

APIChatGPT
  • Dudley & Shanley Inc. Has $8.85 Million Stake in Waters Corporation $WAT

  • Waters (NYSE:WAT) Director Sells $1,442,930.44 in Stock

  • Waters Q2 Earnings Call Highlights

  • Waters Corporation $WAT Shares Acquired by Empowered Funds LLC

  • Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

  • Cetera Investment Advisers Grows Stock Holdings in Waters Corporation $WAT

  • Waters Corporation (WAT) Q2 2026 Earnings Call Transcript

  • Waters (WAT) Q2 Earnings and Revenues Beat Estimates

  • Is Waters Corp (WAT) Holding Value Amidst Q2 Losses? Earnings Beat Estimates with Revenue of $1.645 Billion -- GF Score: 94/100

  • Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

  • Madison Mid Cap Fund Q2 2026 Portfolio Activity

  • Waters (WAT) Earnings Expected to Grow: Should You Buy?

  • Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?

  • Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

  • Assetmark Inc. Grows Stock Holdings in Waters Corporation $WAT

  • Nestle to Offload Half of Waters Business in Joint Venture With Platinum Equity

  • PitchBook Named Best Alternative Data Provider in Waters Technology Rankings 2026

  • Waters Corporation Is Getting Awfully Pricey

  • Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call

  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine